Search Results

You are looking at 41 - 50 of 286 items for :

  • "risk assessment" x
  • Refine by Access: All x
Clear All
Full access

Manisha H. Shah, Whitney S. Goldner, Al B. Benson III, Emily Bergsland, Lawrence S. Blaszkowsky, Pamela Brock, Jennifer Chan, Satya Das, Paxton V. Dickson, Paul Fanta, Thomas Giordano, Thorvardur R. Halfdanarson, Daniel Halperin, Jin He, Anthony Heaney, Martin J. Heslin, Fouad Kandeel, Arash Kardan, Sajid A. Khan, Boris W. Kuvshinoff II, Christopher Lieu, Kimberly Miller, Venu G. Pillarisetty, Diane Reidy, Sarimar Agosto Salgado, Shagufta Shaheen, Heloisa P. Soares, Michael C. Soulen, Jonathan R. Strosberg, Craig R. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Namrata Vijayvergia, Terence Wong, Beth Lynn, and Cindy Hochstetler

than histologic diagnosis. The presence of hormone-staining granules without a clinical syndrome does not make a tumor “functioning.” Thus, functional status is usually not included in the pathology report. Principles of Genetic Risk Assessment and

Full access

Peter F. Coccia, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Alberto S. Pappo, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Bradley J. Zebrack, Hema Sundar, and Dorothy A. Shead

AYA patients with inherited or familial risk factors (see the NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Genetic/Familial High-Risk Assessment: Breast and Ovarian, available at ). Table 2 Age-Specific SEER

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

be given in this circumstance, but persistent tenderness, swelling, or any palpable abnormality warrants further evaluation. Diagnosis and Workup and Risk Assessment Imaging and Blood Tests If an intratesticular mass is identified

Full access

Patrick A. Brown, Bijal Shah, Anjali Advani, Patricia Aoun, Michael W. Boyer, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Nitin Jain, Suzanne Kirby, Michaela Liedtke, Mark Litzow, Aaron Logan, Selina Luger, Lori J. Maness, Stephanie Massaro, Ryan J. Mattison, William May, Olalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Jeffrey E. Rubnitz, Geoffrey L. Uy, Madhuri Vusirikala, Matthew Wieduwilt, Beth Lynn, Ryan A. Berardi, Deborah A. Freedman-Cass, and Mallory Campbell

risk. 29 , 30 The POG and CCG have since merged to form the Children’s Oncology Group (COG) and subsequent risk assessment has produced additional risk factors, particularly in precursor B-ALL, to further refine therapy. Specifically, in B-ALL, a group

Full access

Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford, and Melinda L. Telli

/Familial High-Risk Assessment: Breast and Ovarian Cancer recommend TP53 testing for individuals with multiple primary tumors, 2 of which belong to the LFS tumor spectrum (ie, sarcoma, breast cancer, adrenocortical carcinoma, brain tumor, leukemia, lung

Full access

Gary H. Lyman and Marek S. Poniewierski

data from a large integrated health system, 48 and further efforts are underway based on prospective clinical trials. 49 Comparison With Physician Risk Assessment A prospective cohort study recently evaluated the correlation between the FN risk

Full access

Luciano J. Costa and Saad Z. Usmani

, because the latter is not considered an aggressive phenotype in the absence of other high-risk features (eg, FISH, elevated lactate dehydrogenase level). Dynamic Risk Assessment Measurable Residual Disease and Posttherapy Imaging Given that some modern MM

Full access

Carlos H. Barcenas, Maryam N. Shafaee, Arup K. Sinha, Akshara Raghavendra, Babita Saigal, Rashmi K. Murthy, Ashley H. Woodson, and Banu Arun

/Familial High-Risk Assessment: Breast and Ovarian, among other established criteria, recommend that women with a history of TNBC at age ≤60 years receive a referral for genetic counseling with possible genetic testing. 9 These referral criteria were initially

Full access

Lori L. DuBenske, Sarina B. Schrager, Terry A. Little, and Elizabeth S. Burnside

screening “if they wish to do so” and annual screening for women aged 45–54. The United States Preventive Services Task Force recommends individualized screening for average-risk women before age 50 advised by risk assessment and shared decision-making (SDM

Full access

Shauna McManus, Alexandra K. Zaleta, Melissa F. Miller, Joanne S. Buzaglo, Julie S. Olson, Sara Goldberger, and Kevin Stein

preserve multidimensionality, including anxiety and depression risk screening subscale items. Additionally, 1 item about tobacco/substance use was kept due to clinical significance for risk assessment. In confirmatory factor analysis, the model explained 59